ReviewBiomedicines2023
Impact of Hyper- and Hypo-Uricemia on Kidney Function.
Review in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 47 citations in OpenAlex.
- Chemiluminescence functionalized magnetic nanoparticles-based biosensor for sensitive detection of glucose, uric acid, and cholesterol.Analytical and bioanalytical chemistry · 2026Article
- Risk factor analysis and predictive model construction and evaluation of fractional uric acid excretion in Chinese inpatients with type 2 diabetes.Scientific reports · 2026Article
- Metabolic and inflammatory mechanisms in uric acid-induced tubular dysfunction: Emerging perspectives.Clinics (Sao Paulo, Brazil) · 2026Article
- Differential associations of transient hyperuricemia and transient hypouricemia with annual changes in estimated glomerular filtration rate in healthy participants: an observational study.BMC nephrology · 2026Observational
- Serum uric acid/creatinine ratio and metabolic-associated fatty liver disease risks in children.Pediatric research · 2026Article
- Endothelin-2 and Its Association with Uric Acid Levels and Systemic Inflammation: Relevance to Chronic Kidney Disease Progression.International journal of molecular sciences · 2026Article
- Study on the pro-inflammatory injury of neutrophil extracellular traps in gouty nephropathy.Frontiers in immunology · 2026Review
- CaSR regulates SLC26A6 expression via the PKA-FOXO4 signaling axis to promote experimental calcium oxalate kidney stone formation in rats.Frontiers in cell and developmental biology · 2026Article
- Nutrient metabolic heterogeneity across renal stages in patients with type 2 diabetes mellitus and diabetic kidney disease.Frontiers in nutrition · 2026Article
- Hyperuricemia-induced kidney injury: a narrative review of mechanisms and therapeutic advances.BMC nephrology · 2025Review
- A simple and rapid colorimetric sensor for uric acid detection based on ligand-modified silver nanoparticles with oxidase activity.Mikrochimica acta · 2025Article
- Association of hyperuricemia with higher miscarriage rates and lower live birth rates in women undergoing IVF/ICSI.Journal of ovarian research · 2025Article
- The Association Between the Hemoglobin Glycation Index and Cardiometabolic Diseases: A Mini-Review.Journal of clinical hypertension (Greenwich, Conn.) · 2025Review
- Prediction for Risk of Hypouricemia in Hospitalized Patients: A Single-center, Retrospective Cohort Study.Internal medicine (Tokyo, Japan) · 2025Article
- Serum Uric Acid/Serum Creatinine Ratio and Chronic Vascular Lesions on Renal Biopsy: A Retrospective Observational Study.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2025Observational
- Insights into renal damage in hyperuricemia: Focus on renal protection (Review).Molecular medicine reports · 2025Review
- Annual change in eGFR in renal hypouricemia: a retrospective pilot study.Clinical and experimental nephrology · 2025Article
- Drug-Induced Hypouricemia.Drug safety · 2025Review
- Molecular and Clinical Perspectives on the Regulation of Sleep and Uric Acid Metabolism.Nature and science of sleep · 2025Review
- Cardiorenal protective effects of Tanhuo decoction in acute myocardial infarction via regulating multi-target inflammation and metabolic signaling pathways.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uric acid (UA) forms monosodium urate (MSU) crystals to exert proinflammatory actions, thus causing gout arthritis, urolithiasis, kidney disease, and cardiovascular disease. UA is also one of the most potent antioxidants that suppresses oxidative stress. Hyper andhypouricemia are caused by genetic mutations or polymorphism. Hyperuricemia increases urinary UA concentration and is frequently associated with urolithiasis, which is augmented by low urinary pH. Renal hypouricemia (RHU) is associated with renal stones by increased level of urinary UA, which correlates with the impaired tubular reabsorption of UA. Hyperuricemia causes gout nephropathy, characterized by renal interstitium and tubular damage because MSU precipitates in the tubules. RHU is also frequently associated with tubular damage with elevated urinary beta2-microglobulin due to increased urinary UA concentration, which is related to impaired tubular UA reabsorption through URAT1. Hyperuricemia could induce renal arteriopathy and reduce renal blood flow, while increasing urinary albumin excretion, which is correlated with plasma xanthine oxidoreductase (XOR) activity. RHU is associated with exercise-induced kidney injury, since low levels of SUA could induce the vasoconstriction of the kidney and the enhanced urinary UA excretion could form intratubular precipitation. A U-shaped association of SUA with organ damage is observed in patients with kidney diseases related to impaired endothelial function. Under hyperuricemia, intracellular UA, MSU crystals, and XOR could reduce NO and activate several proinflammatory signals, impairing endothelial functions. Under hypouricemia, the genetic and pharmacological depletion of UA could impair the NO-dependent and independent endothelial functions, suggesting that RHU and secondary hypouricemia might be a risk factor for the loss of kidney functions. In order to protect kidney functions in hyperuricemic patients, the use of urate lowering agents could be recommended to target SUA below 6 mg/dL. In order to protect the kidney functions in RHU patients, hydration and urinary alkalization may be recommended, and in some cases an XOR inhibitor might be recommended in order to reduce oxidative stress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.